Ebola virus disease (EVD), also known as Ebola hemorrhagic fever (EHF) or simply Ebola; is a viral hemorrhagic fever of humans and other primates caused by ebolaviruses. Viruses of the genus Ebolavirus cause sporadic outbreaks of severe haemorrhagic fever; with case fatality of up to 90%.
Responding to any filovirus outbreak is challenging and requires a combination of clinical, laboratory, and epidemiological approaches to halt virus transmission. Response to this outbreak continues to be extremely challenging; with a precarious security situation hampering case finding; contact tracing, decontamination, and other standard response activities. however, in generating EBOV sequences from samples collected from patients in the region.
Infectious ebola virus
But each outbreak is thought to be a separate introduction into the human population from an unknowing natural reservoir. We do not know if the host is dispersed; and virus transmitting among a widespread population; or if virus persists in groups of mobile hosts; which must contend with geographical features; such as rivers or mountains.
Two experimental Ebola treatments being using in the current outbreak in eastern Democratic Republic of the Congo have provding effective in laboratory tests with human cells; according to the U.S. Centers for Disease Control and Prevention. The tests showing that the treatments the antiviral remdesivir and antibodies in the ZMapp treatment blocked growth of the Ebola virus strain causing the outbreak.
However the findings suggesting that the two treatments hold promise for enabling patients to recover from the deadly illness; according to the CDC. But all of the treatments being testing in the current DRC outbreak were developing to fight Ebola viruses from previous outbreaks.
RNA viruses are always mutating and because Ebola is an RNA virus it’s vitally important to make sure existing treatments work against the virus that’s making people sick now. The anti-arrhythmic drug amiodarone hydrochloride; was previously shown to block EBOV entry in vitro; and was giving to patients in west Africa but its clinical benefits remain unclear. But the study finding that inhibition of infection by amiodarone hydrochloride was similar for EBOV-Ituri and EBOV-Makona.